SCHEMBL2366448

SCHEMBL2366448

Cc1cc(C2CC2)cnc1N1CCN(C(=O)c2ccc(N3C(=O)OC[C@H]3C)cc2C#N)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 5/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTT P42858 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 3/20 0.35
CASP1 P29466 3/20 0.35
CASP7 P55210 3/20 0.35
HSD17B10 Q99714 3/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
USP2 O75604 2/20 0.35
MAPT P10636 2/20 0.35
ALOX15 P16050 1/20 0.35
FASN P49327 8/20 0.35
CFTR P13569 2/20 0.34
GAA P10253 1/20 0.34
CLK1 P49759 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366456 1.00 KDM4E (0.36) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2365892 0.91 ALDH1A1 (0.35) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2365899 0.91 ALDH1A1 (0.35) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2365949 0.90 CFTR (0.39) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2365940 0.90 CFTR (0.39) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2365935 0.90 LMNA (0.35) KDM4EALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL2365925 0.90 LMNA (0.35) KDM4EALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL2366497 0.89 ALDH1A1 (0.36) KDM4EALDH1A1TDP1HTTSMN1; SMN2
SCHEMBL2366501 0.89 ALDH1A1 (0.36) KDM4EALDH1A1TDP1HTTSMN1; SMN2
Hydrochloric Acid SCHEMBL2366534 0.88 IDH1 (0.38) KDM4EHTTLMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 KDM4E 1064/4885ALDH1A1 598/4885TDP1 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.